Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research[1][2][3].
Golimumab (CNTO-148) (0.1-10 μg /mL; 24-72 hours; transmembrane TNFα-transfected Jurkat cells) induces reductions in the viability of transmembrane TNFα-expressing cells[1].
Golimumab (CNTO-148) (10 μg /mL; 48 hours; transmembrane TNFα-transfected Jurkat cells) induces apoptosis, increase the levels of active caspase-3 and induces apoptotic DNA fragmentation[1].
Cell Viability Assay[1]
| Cell Line: | Transmembrane TNFα-transfected Jurkat cells |
| Concentration: | 0.1, 1 and 10 μg/mL |
| Incubation Time: | 24, 48 and 72 hours |
| Result: | Reduced cell viability in a dose- and time-dependent manner. |
Apoptosis Analysis[1]
| Cell Line: | Transmembrane TNFα-transfected Jurkat cells |
| Concentration: | 10 μg /mL |
| Incubation Time: | 48 hours |
| Result: | Had the percentage of apoptotic cells for 30.29%. |
Western Blot Analysis[1]
| Cell Line: | Transmembrane TNFα-transfected Jurkat cells |
| Concentration: | 10 μg /mL |
| Incubation Time: | 48 hours |
| Result: | Increased the levels of active caspase-3 and induces apoptotic DNA fragmentation. |
Golimumab (CNTO-148) (24 mg/kg; i.h.; daily, for 7 days; swiss-albino healthy male mice) inhibits oxidative stress, apoptotic cell death inflammatory response, thus improving renal function. Golimumab reduces all markers of kidney injury and attenuates cell death[2].
Golimumab (CNTO-148) (1-10 mg/kg; i.p.;daily; for 4 weeks; Tg197 transgenic mouse model) relieves TNFα-induced arthritis in a mouse model of human[3].
| Animal Model: | Swiss-albino healthy male mice[2] |
| Dosage: | 24 mg/kg |
| Administration: | Subcutaneous injection; daily, for 7 days |
| Result: | Reduced serum parameters like BUN, NGAL creatinine, cystatin C, and urinary parameters like KIM-1, NAG, albumin clusterin. |
| Animal Model: | Swiss-albino healthy male mice[2] |
| Dosage: | 24 mg/kg |
| Administration: | Subcutaneous injection; daily, for 7 days |
| Result: | Inhibited oxidative stress, reduces MDA concentrations and increases the GSH and catalase levels. |
| Animal Model: | Swiss-albino healthy male mice[2] |
| Dosage: | 24 mg/kg |
| Administration: | Subcutaneous injection; daily, for 7 days |
| Result: | Inhibitd cisplatin-induced inflammation, decreased TNF-α, including IL-6, IL-1β, MCP-1, ICAM-1, and TGF-β1 levels and increases IL-10 concentrations, reduced caspase 3 in cisplatin injected mice kidneys. |
| Animal Model: | Tg197 transgenic mouse model[3] |
| Dosage: | 1 and 10 mg/kg |
| Administration: | Intraperitoneal injection;for 4 weeks |
| Result: | Reduced the arthritic index. |
